速递｜明星口服减重药误当作“美容捷径”！专家这样提醒

Core Viewpoint - The recent approval of oral semaglutide, a GLP-1 class drug, by the FDA for weight management has reignited public interest in easier weight loss methods [6] Mechanism of Action - Semaglutide does not directly burn fat; instead, it acts as a GLP-1 analog that regulates blood sugar and energy metabolism by promoting insulin secretion, inhibiting glucagon release, and delaying gastric emptying, which reduces hunger and food intake [8] - The oral formulation requires higher doses due to lower absorption efficiency in the gastrointestinal tract and has strict administration requirements, such as taking it on an empty stomach with minimal water [8] Clinical Indications - Current weight loss prescription drugs in China primarily consist of GLP-1 class medications, suitable for individuals with a BMI ≥ 28 or BMI ≥ 24 with obesity-related conditions [9] - The only over-the-counter weight loss drug available is orlistat, which has notable tolerance and side effect issues [9] - New-generation weight loss drugs targeting multiple pathways show potential but require ongoing observation for long-term safety and tolerance [9] Risks and Management - The emergence of oral formulations raises concerns about drug misuse, particularly among individuals with normal weight seeking rapid weight loss, which can lead to adverse health effects [9] - Weight management should not solely rely on medication; lifestyle changes such as dietary adjustments, regular exercise, and adequate sleep are essential for sustainable weight control [10] Sustainable Weight Management - The focus of weight loss should extend beyond just reducing numbers on the scale to preserving muscle mass and maintaining metabolic health through adequate protein intake and resistance training [10] - Any medication use should be under medical supervision, with a clear strategy for weight maintenance post-medication [10]